PSID Recent news! PositiveID Analyst Report Issued by Small Cap IR: BioThreat Detection Contender Continues Progress
6 hours 1 minutes ago - DJNF
NEW YORK, Jan. 29, 2015 /PRNewswire/ -- Analyst report issued by Small Cap IR. PositiveID Corp. (OTCQB: PSID) based in Delray Beach and Pleasanton, CA Fla. is a developer of biological detection and diagnostics solutions, announced today that it has completed the design of the second-phase (bench-top) prototype, the first major milestone in the development of the Firefly Dx second-phase prototype. With the completion of this design, the Company has begun to build the second-phase prototype of Firefly Dx, a real-time, handheld, polymerase chain reaction (PCR) pathogen detection system, which it expects to complete during the first half of 2015.
So far this year, the stock is down about 22.07%. The stock popped back during October amid the Ebola, where it reached $0.07. Positive ID reported a revenue of $325,000 for Q3 2014, the first revenue generation since its business launching in 2011. The Q4 results should be released soon.
On January 14, 2015, the company announced that it had completed the design of the second-phase (bench-top) prototype - the first major milestone in the development of the Firefly Dx second phase prototype. PositiveID has begun to build the second-phase prototype, which is expected to be completed during the first half of 2015. This would be considered a significant update in term of company operation. Also, the firm had entered into a strategic financing of $4 million that would enabled the company to bring its Firefly technology to field testing and commercialization.
6 hours 1 minutes ago - DJNF
NEW YORK, Jan. 29, 2015 /PRNewswire/ -- Analyst report issued by Small Cap IR. PositiveID Corp. (OTCQB: PSID) based in Delray Beach and Pleasanton, CA Fla. is a developer of biological detection and diagnostics solutions, announced today that it has completed the design of the second-phase (bench-top) prototype, the first major milestone in the development of the Firefly Dx second-phase prototype. With the completion of this design, the Company has begun to build the second-phase prototype of Firefly Dx, a real-time, handheld, polymerase chain reaction (PCR) pathogen detection system, which it expects to complete during the first half of 2015.
So far this year, the stock is down about 22.07%. The stock popped back during October amid the Ebola, where it reached $0.07. Positive ID reported a revenue of $325,000 for Q3 2014, the first revenue generation since its business launching in 2011. The Q4 results should be released soon.
On January 14, 2015, the company announced that it had completed the design of the second-phase (bench-top) prototype - the first major milestone in the development of the Firefly Dx second phase prototype. PositiveID has begun to build the second-phase prototype, which is expected to be completed during the first half of 2015. This would be considered a significant update in term of company operation. Also, the firm had entered into a strategic financing of $4 million that would enabled the company to bring its Firefly technology to field testing and commercialization.
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
